Last reviewed · How we verify
IgNextGen 10%
IgNextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.
IgNextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy).
At a glance
| Generic name | IgNextGen 10% |
|---|---|
| Sponsor | CSL Limited |
| Drug class | Intravenous immunoglobulin (IVIG) |
| Target | Fc receptors; multiple pathogenic antigens and antibodies |
| Modality | Small molecule |
| Therapeutic area | Immunology; Hematology |
| Phase | Phase 3 |
Mechanism of action
As a 10% concentration IVIG, this product contains polyvalent human immunoglobulins (primarily IgG) derived from pooled plasma donations. It works through multiple mechanisms including antibody replacement in immunodeficiency states, immune modulation via Fc receptor engagement, and neutralization of pathogenic antibodies and antigens. The higher 10% concentration allows for smaller infusion volumes compared to lower-concentration formulations.
Approved indications
- Primary immunodeficiency disorders
- Secondary immunodeficiency
- Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)
Common side effects
- Headache
- Fever
- Chills
- Infusion-related reactions
- Thrombosis
- Renal dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IgNextGen 10% CI brief — competitive landscape report
- IgNextGen 10% updates RSS · CI watch RSS
- CSL Limited portfolio CI